Melanoma Condition Center Debuts

Published Online: Thursday, September 13, 2012
Follow Pharmacy_Times:
This month, we introduce a new condition center on www.PharmacyTimes.com covering melanoma, which accounts for approximately 5% of skin cancers, but is responsible for 3 times as many deaths as all other skin cancers combined. Once rare, melanoma’s incidence has increased along with people’s exposure to ultraviolet radiation from the sun.

Although anyone can develop melanoma, genetic factors can increase one’s risk, including having a light complexion, an inability to tan, red hair, blue eyes, or familial mole/melanoma syndrome. The first-line treatment for melanoma is surgical removal of the malignant lesion and a margin of healthy skin, but a number of medications play a role in treatment as well.

Some topics that will be covered in the melanoma condition center include:
  • A smartphone app that helps track moles that may indicate the development of melanoma
  • The discovery of a T-cell with the potential to help fight melanoma
  • The promise of combination therapy in treating melanoma


Related Articles
Citing a risk of spreading unsuspected cancer, the FDA is advising against the use of laparoscopic power morcellators in the removal of the uterus or fibroids in the majority of women.
Amgen has discontinued its studies on rilotumumab in advanced gastric cancer after an increased number of deaths were reported among patients receiving rilotumumab and chemotherapy, compared with those only undergoing chemotherapy.
Clinical practice guidelines for the diagnosis and treatment of certain types of cancer are surprisingly unstandardized.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Latest Issues
$auto_registration$